Clinical study on the effectiveness of long-acting octreotide in acromegaly patients after surgery or gamma knife therapy of growth hormone-secreting pituitary adenoma
10.3760/cma.j.issn.1673-4904.2017.11.006
- VernacularTitle:长效奥曲肽治疗垂体生长激素瘤手术或伽马刀治疗后未缓解的肢端肥大症患者的临床研究
- Author:
Fang WANG
1
;
Liyong ZHONG
Author Information
1. 100050,首都医科大学附属北京天坛医院内分泌科
- Keywords:
Acromegaly;
Growth hormone-secreting pituitary adenoma;
Octreotide;
Insulin-like growth factor Ⅰ
- From:
Chinese Journal of Postgraduates of Medicine
2017;40(11):982-985
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effectiveness of long-acting octreotide in the treatment of acromegaly patients who did not achieve biochemical control after neurosurgery or gamma knife therapy of growth hormone-secreting pituitary adenoma. Methods Six acromegaly patients who received long-acting octreotide treatment regularly were included. Five patients had received prior trans-sphenoidal surgery and 1 patient had received prior gamma knife therapy before admission. All patients were admitted monthly for evaluation of pituitary-target gland function and octreotide therapy. Data of treatment with octreotide for 6 months were retrospectively summarized. Results Symptoms were reported to be alleviated. Two patients achieved biochemical control of the disease. Two patients had fasting growth hormone level less than 2.5 μg/L,but insulin-like growth factor-1(IGF-1)level was still higher than the age-adjusted normal range.Another 2 patients had decreased growth hormone and IGF-1 level, but both still higher than the normal range. Compared with baseline, IGF-1 level was decreased after treatment:(371.83 ± 217.46)μg/L vs.(713.33 ± 198.29)μg/L,and there was statistical difference (P = 0.017). There were no statistical differences in glycated hemoglobin and fasting plasma glucose before and after octreotide treatment (P > 0.05). Conclusions For acromegaly patients who do not achieve biochemical control after neurosurgery or gamma knife therapy, long-acting octreotide can effectively control IGF-1 level and increase the biochemical control rate of the disease.
